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Abstract
The ovarian follicle luteinizing hormone (LH) signaling molecules that regulate oocyte meiotic maturation have recently
been identified. The LH signal reduces preovulatory follicle cyclic nucleotide levels which releases oocytes from the
first meiotic arrest. In the ovarian follicle, the LH signal reduces cyclic nucleotide levels via the CNP/NPR2 system, the
EGF/EGF receptor network, and follicle/oocyte gap junctions. In the oocyte, reduced cyclic nucleotide levels activate the
maturation promoting factor (MPF). The activated MPF induces chromosome segregation and completion of the first and
second meiotic divisions. The purpose of this paper is to present an overview of the current understanding of human LH
signaling regulation of oocyte meiotic maturation by identifying and integrating the human studies on this topic. We
found 89 human studies in the literature that identified 24 LH follicle/oocyte signaling proteins. These studies show that
human oocyte meiotic maturation is regulated by the same proteins that regulate animal oocyte meiotic maturation. We
also found that these LH signaling pathway molecules regulate human oocyte quality and subsequent embryo quality.
Remarkably, in vitro maturation (IVM) prematuration culture (PMC) protocols that manipulate the LH signaling path-
way improve human oocyte quality of cultured human oocytes. This knowledge has improved clinical human IVM
efficiency which may become a routine alternative ART for some infertile patients.
Keywords Oocyte meiotic maturation . LH follicle signaling . Oocyte quality
Introduction
Ovarian follicular development and its endocrine function
have been the major focus of mammalian ovarian research.
Ovarian follicular development has been extensively reviewed
[1, 2]. The animal oocyte has received less attention and the
human oocyte even less. Pincus reviewed mammalian oogen-
esis in 1936 [3]. Since these initial studies, much has been
learned about the control of oogenesis [4], oocyte maturation
[5], oocyte-granulosa cell interactions [6], and cellular organi-
zation of the oocyte [7]. Oocyte meiotic maturation is a vital
process required for oocyte development. During this process,
the LH surge releases oocytes from meiotic prophase arrest
and induces resumption of oocyte meiosis and completion of
the first meiotic division [8]. This process is initiated when an
LH signal is generated in the ovarian follicle. LH binds the
mural granulosa cell LH receptor (LHR), activating a G pro-
tein which activates the cAMP system. Now, we know that
this LH signal targets proteins in both the follicle compartment
and the oocyte that regulate oocyte meiotic maturation. The
primary targets of the LH signal in the ovarian follicle com-
partment are the CNP/NPR2 system, the EGF network, and
gap junctions [9, 10]. The primary target of the LH signal in
the oocyte is the maturation promoting factor (MPF) [11].
Activation of the MPF phosphorylates the SAC, APC/C sys-
tems, and other downstream proteins which induce progres-







1 Boston IVF - The Syracuse Center, 5792 Widewaters Pkwy.,
Syracuse, NY 13214, USA
2 Department of Obstetrics and Gynecology, SUNY Upstate Medical
University, 736 Irving Ave., Syracuse, NY 13210, USA
3 CNY Fertility, 835 Hopkins Rd., Buffalo, NY 14221, USA
4 Department of Obstetrics and Gynecology, Division of Reproductive
Endocrinology and Infertility, University of Massachusetts Medical
School, 119 Belmont St., Worcester, MA 01655, USA
Reproductive Sciences (2020) 27:1223–1252
https://doi.org/10.1007/s43032-019-00137-x
The Author(s) 2019
chromosome condensation, and chromosome segregation.
These findings were made in animal models. The cell biology
of human oocyte meiotic maturation is less clear.
Oocyte meiotic maturation begins with the mid-cycle LH
surge and ends with the formation of a mature oocyte just prior
to ovulation (Fig. 1) [12]. The cardinal feature of oocyte mei-
otic maturation is the formation of a metaphase II–arrested
haploid oocyte. LH initiates oocyte meiotic maturation. The
induction of oocyte maturation by pituitary gonadotropins
was first demonstrated by Heilbrunn in 1939 in frogs.
Oocyte maturation begins with the conversion of germinal
vesicle (GV) oocytes to MI oocytes then to MII oocytes
(Fig. 1). GV oocytes are arrested in prophase I, and may be
arrested for up to 50 years in women. The first visible sign of
oocyte meiotic maturation is breakdown of the oocyte nuclear
membrane referred to as germinal vesicle breakdown
(GVBD). This is followed by chromosome condensation
and alignment of the chromosomes at the metaphase plate at
metaphase I. These oocytes are referred to as metaphase I (MI)
oocytes. This is followed by the first oocyte meiotic division,
extrusion of the first polar body and formation of a secondary
oocyte (mature egg) that arrests at metaphase II until fertiliza-
tion when the second meiotic division is completed. The mo-
lecular mechanisms underlying oocyte meiotic maturation
have recently been identified in animals.
LH triggers an explosion of molecular activity in follicle
somatic cells [10, 12, 13]. This activates the oocyte maturation
promoting factor (MPF) which, in turn, initiates oocyte chro-
mosome segregation. The genesis of the LH signal is the ac-
tivation of G protein–coupled receptors in mural granulosa
cells by the mid-cycle LH surge causing a cAMP spike in
the follicular compartment [9, 14, 15]. This rapidly (20 min)
suppresses CNP [16] and NPR2 [17], activates the EGF net-
work, and closes gap junctions. The result is reduced oocyte
cGMP levels, activation of phosphodiesterase 3A (PDE3A),
reduction of oocyte cAMP levels, activation of CDK1 which
initiates resumption of meiosis I, followed by chromosome
segregation, completion of the first meiotic division, and the
formation of an MII oocyte [11, 18]. The formation of a MII
oocyte indicates the completion of final oocyte meiotic matu-
ration which is required for the acquisition of oocyte develop-
mental competence.
Most human oocytes retrieved during in vitro fertilization
(IVF) are not developmentally competent to form a viable
blastocyst [19, 20]. It is important to understand how oocytes
acquire developmental competence also referred to as oocyte
quality during oogenesis since this is the primary factor re-
sponsible for reproductive success. A developmentally com-
petent oocyte is able to develop a mature oocyte, fertilize,
cleave, form a blastocyst, implant, and develop into a normal
fetus. Oocyte quality is acquired during the process of oogen-
esis which begins in fetal development during the formation of
primordial germ cells and primary oocytes, and ends during
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Fig. 1 Human folliculogenesis, oogenesis, and oocyte meiotic
maturation. a Gonadotropins regulate folliculogenesis, oogenesis,
oocyte meiotic maturation, and oocyte competence. The first visible
sign of meiotic progression is oocyte germinal vesicle breakdown
(GVBD) followed by expulsion of the first polar body. The mid-cycle
LH surge activates the oocyte maturation promoting factor (MPF) which
initiates resumption of meiosis. The MPF activates the oocyte anaphase-
promoting complex (APC) which promotes completion of the first mei-
otic division. MII oocytes remain arrested in metaphase II until fertiliza-
tion induces completion of the second meiotic division. Oocyte meiotic
maturation beginswith the LH surge and ends at metaphase II. Competent
oocytes support the subsequent development of blastocysts. b Human
germinal vesicle (GV), MII oocyte (MII), and blastocyst
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division (Fig. 1) [12]. Attainment of oocyte developmental
competence requires completion of oocyte cytoplasmic and
meiotic maturation [21]. Many cellular processes are respon-
sible for oocyte competence; the major genes responsible for
oocyte quality are not yet known [5, 7, 22].
Very little research has been devoted to the human oocyte
due to the lack of available human oocytes for research. Most
human oocyte research has occurred in the last 40 years with
the more readily available supply of human oocytes from the
development of human IVF. Most human oocyte studies ob-
tain research oocytes from IVF clinics. The number of human
oocyte publications is still limited, as are reviews on LH sig-
naling in human oocyte meiotic maturation [5, 23, 24].
The purpose of this paper is to provide an updated review
on this topic. We found 89 human studies in the literature that
identified 24 LH signaling pathway proteins involved in hu-
man oocyte meiotic maturation (Table 1). These studies show
that these ovarian follicle signaling proteins and oocyte cell
cycle proteins not only regulate animal and human oocyte
meiotic maturation, but also oocyte competence and embryo
quality. In addition, we review studies that demonstrate that
human oocyte and embryo quality can be improved by ma-
nipulating the LH signaling pathway (Table 2). Experimental
human in vitro maturation (IVM) studies that incorporate a
prematuration culture (PMC) interval manipulated to maintain
high cAMP levels by treating with cAMP phosphodiesterase
inhibitors or adenylate cyclase stimulators or supplementing
with LH signaling pathway molecules; i.e., AREG improves
human oocyte competence and embryo quality [101]. This
knowledge has helped to improve clinical human IVM effi-
ciency which now is approaching standard IVF efficiency.
Follicle and Oocyte Development
The functional unit of the ovary is the follicle. The primary
function of the follicle is to support the development of a
competent mature oocyte. The follicle contains a single oocyte
surrounded by granulosa cells. Follicular growth and develop-
ment are complex processes that begin in fetal development
and end in about 50 years in most women [1]. The oocyte
originates from oogonia which arise from primordial germ
cells which first appear in the yolk sac around the third week
of gestation. Primordial germ cells migrate to the genital ridge
around the fifth week of gestation where they divide by mito-
sis forming approximately 7 million oogonia during the fifth
month of gestation. Primary oocytes form from oogonia when
they divide by meiosis. Primary oocytes that are surrounded
by a single layer of spindle-shaped cells, the precursors of
granulosa cells (GCs), are called primordial follicles which
Table 1 LH signaling proteins
regulate human oocyte meiotic
maturation
Follicle/oocyte protein Protein type Reference(s)
Follicle granulosa cell proteins
1. LH receptor G protein–coupled receptor [25–33]
2. Adenylate cyclase 7 and 9 Enzyme [30]
3. CNP Natriuretic peptide [16, 34, 35]
4. EGF Growth factor [35–40]
5. AREG Growth factor [33, 35, 41–46]
Follicle cumulus cell proteins
6. NPR2 Guanylate cyclase [34]
7. EGF receptor (eRB1) Tyrosine kinase receptor [35, 38]
8. Cx43 Channel [47–55]
9. BMPRII Serine/threonine kinase [29, 56, 57]
10. SMAD2/3 Transcription factor [56, 58–60]
Oocyte-specific factors
11. GDF9 Growth factor [25, 61–71]
12. BMP15 Growth factor [56, 57, 72–77]
Oocyte signaling proteins
13. GPR3 G protein–coupled receptor [78]
14. AC3 Enzyme [78]
15. PDE3A Enzyme [78]
Oocyte MPF complex (cell cycle control)
16. CDK1 Serine/threonine kinase [25, 79–81]
17. Cyclin B1 Cyclin [81, 82]
18. WEE1B Serine/threonine kinase [80, 83]
19. CDC25 Phosphatase [25, 84]
Oocyte SAC (cell cycle control)
20. Bub1, BubR1, Bub3 Serine/threonine kinase [25, 80–82, 85–87]
21. CDC20 Heterotrimeric G protein [82]
Chromosome segregation (cell cycle control)
22. APC (ANAPC1, 4, and 11) Ubiquitin ligase [81, 82, 88]
23. Securin-separase Protease [81, 82, 88]
24. Cohesin (SMC1, REC8, STAG3) ATPases [81, 89–92]
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appear during the fifth month of gestation in humans. The
spindle-shaped cells differentiate into granulosa cells which
proliferate transforming the primordial follicle into a primary
follicle. A degenerative process called atresia reduces the
number of oocytes from seven million to one million at birth
to 500,000 at menarche. Primary oocytes, primordial follicles,
and primary follicles remain arrested in the diplotene stage of
prophase I until puberty when the ovarian cycle begins.
Much of our understanding of follicular development
comes from studies of the rodent 4-day estrus cycle.
Pedersen described five follicle stages in the mouse ovary:
primordial, primary, secondary (preantral), tertiary (antral),
and preovulatory (Graafian) [102]. Primordial follicles contin-
uously leave the non-growing oocyte pool starting at puberty.
The conversion of dormant primordial follicles to growing
primary follicles is a critical step in folliculogenesis. Primary
follicles are composed of cuboidal granulosa cells, a basal
lamina, and a 20-μm-diameter primary oocyte. The nature of
the converting signal is not yet known [103, 104]. Primary
follicles are converted to secondary follicles, and these are
composed of two layers of GCs, a zona pellucida, and theca
cells. Secondary follicles produce estrogen, progesterone, and
androgens and express gap junctions.
The tertiary follicle or antral follicle develops a space filled
with follicular fluid called an antrum, which grows reaching a
diameter of 2–5 mm. At this stage, 2 million follicle somatic
cells, mural granulosa cells (mGCs) and cumulus cells (CCs),
surround the oocyte. The theca interna and externa are formed,
LH receptors appear, and estrogen becomes the dominant ste-
roid hormone of the follicle as a result of increased follicular
steroidogenesis activity. Antral follicle growth is dependent
on follicle-stimulating hormone (FSH) and luteinizing hor-
mone (LH). The preovulatory follicle mean diameter is
20 mm [18–24, 101], and mean follicular volume is 3.8 ml
(3.1–8.2). The oocyte at this stage attains a maximum diame-
ter of 70 μm.
The ovarian cycle refers to three reproductive processes:
folliculogenesis, ovulation, and formation of the corpus
luteum. Folliculogenesis, which is highly regulated, refers to
the process of ovarian follicle growth and differentiation that
primarily occurs during the menstrual cycle. Gougeon de-
scribed five stages of human follicle development based on
follicular size and granulosa cell numbers: primordial folli-
cles, primary follicles, secondary follicles, antral follicles,
and preovulatory follicles [105, 106]. The primordial follicle
is surrounded by a single layer of pre-granulosa cells, and it
has a mean diameter of 30 μm. They appear in the fetus at
16 weeks gestation. At this stage, follicular growth is gonad-
otropin independent. Primary follicles contain a single layer of
cuboidal GCs, they develop a zona pellucida, and oocyte gap
junctions (GJs) appear. They appear at 20 weeks gestation.
In the next stages of maturation, follicle growth becomes
gonadotropin dependent. GCs proliferate increasing to 600,
and the oocyte grows resulting in a secondary follicle. At this
point, the follicle diameter is 120 μm, the oocyte diameter
increases to 80 μm, and the germinal vesicle (GV) diameter
is 25 μm. FSH, LH, androgen, and estrogen receptors appear.
Theca cells and GJs appear. In the next phase (class 4), folli-
cles grow to a diameter of 2 mm, GC proliferation increases to
370,000, and the antrum appears. This follicle is called a
Graafian follicle. The oocyte now has an eccentric position
and is surrounded by multiple layers of GC which are called
cumulus cells (CCs).
Follicular maturation refers to the formation of the preovu-
latory follicle from the tertiary follicle which occurs during the
15 days of the follicular phase [106]. In this phase, the antral
follicle becomes a preovulatory follicle or dominant follicle,
follicle growth becomes exponential, and the oocyte acquires
full developmental competence. The follicle size increases
from 5 to 20 mm, GC numbers increase from 370,000 to 50
million, and the oocyte diameter increases to 120 μm. Growth
of the dominant follicle is stimulated by FSH, estrogen pro-
duction increases, the antrum grows, and LH receptors appear.
Oocyte capacitation and final oocyte maturation occur dur-
ing the first 15 days (follicular phase) of the menstrual cycle
[107]. The oocyte reaches its full developmental capacity re-
ferred to as full developmental competence during the preovu-
latory stage prior to the LH surge (Fig. 1). The acquisition of
full competence is referred to as oocyte capacitation which is
primarily FSH dependent. Oocyte competence is correlated to
follicle diameter. Preovulatory follicles with 15–25-mm diam-
eters generally contain competent oocytes. At this point, the
oocyte is ready to undergo final oocyte meiotic maturation.
The mid-cycle LH surge releases oocytes from prophase arrest
and induces chromosome segregation, completion of the first
meiotic division, extrusion of the first polar body, and ovula-
tion of the secondary oocyte into the fallopian tube.
The terms recruitment, selection, and dominance describe
ovarian follicle maturation during the follicular phase of the
menstrual cycle [107]. In the early follicular phase, a cohort of
primordial follicles matures while many others degenerate by
atresia. This pattern of follicle growth and atresia has been
referred to as the “trajectory of follicle growth”. The term
recruitment refers to the process by which a follicle cohort
enters the growth trajectory. Selection refers to the process
that reduces the recruited follicle cohort to one follicle.
Selection occurs in the early follicular phase. Dominance re-
fers to the one follicle being selected to ovulate [108]. It be-
comes dominant 7 days before ovulation. Estradiol production
increases and becomes the primary steroid in dominant folli-
cles. Estradiol levels are different in the ovarian veins by days
5 to 7 of the cycle [109]. Intrafollicular estradiol levels peak in
the dominant follicle in the late follicular phase. This is
followed by the mid-cycle LH surge. At the beginning of the
LH surge, intrafollicular E2 levels decrease, and progesterone
levels increase which reflects GC luteinization [110]. In
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women, the mid-cycle LH surge triggers GVBD, cumulus cell
expansion, and extrusion of the first polar body at 15, 22, and
35 h after the start of the LH surge, respectively (Fig. 1) [111].
Luteinizing Hormone Receptor
Mid-cycle Luteinizing Hormone Surge
The menstrual cycle is under neuroendocrine control.
Luteinizing hormone (LH) is a member of the pituitary
glycoprotein hormone family which consists of LH, FSH,
HCG, and TSH. Each is a heterodimer glycoprotein com-
posed of two non-covalently bound polypeptide subunits.
They each contain an identical alpha subunit and a
hormone-specific beta subunit. The human LHβ, FSHβ,
and hCGβ subunits are composed of 121, 110, and 145
amino acids, respectively. The human common α subunit
is composed of 92 amino acids. In humans, the LH beta
subunit and hCG gene are located on chromosome 19, FSH
beta is on chromosome 11, and the common alpha is on
chromosome 6. Cloning and DNA sequence of the gene
encoding the bovine beta FSH chain were determined in
1986 [112]. Both gonadotropins are synthesized and stored
in pituitary gonadotrope granules. Both LH and FSH exist
within a single gonadotrope population in the anterior pi-
tuitary consistent with the combined secretion of LH and
FSH at mid-cycle in humans.
The onset of the LH surge occurs on cycle day 15 of the
menstrual cycle. The LH surge is characterized by a 10-fold
increase in LH levels in the peripheral circulation [113]. The
mean duration of the LH surge is 4 days. How serum LH
reaches the mural granulosa cells is not clear; however, LH
binds the LH receptor, inducing oocyte maturation and ovu-
lation, 36 and 40 h respectively, after the beginning of the LH
surge. The mid-cycle LH surge is induced by circulating es-
trogen. Mean estradiol levels peak at 200 pg/ml at the end of
the follicular phase. This rise in circulating estradiol induces
the pituitary LH surge. Estrogen induces the LH surge by
acting on the pituitary and hypothalamus. Whether the
Table 2 Effect of IVM/PMC on human oocyte and embryo quality
Groups MII FR CR BR
cAMP-modulated IVM systems
ND, [93] Conventional IVM 46%a 60%
2006 PMC-PDE-I 67%a 58%
SYM, [94] Conventional IVM 55.6% 52%a 16.7% 5%
2008 PMC-PDE-I 59.7% 65% 20.8% 8.7%
PMC-Forskolin 62.8% 67% 15.4% 10.2%
PMC-PDE-I + forskolin 65.4% 76.3%a 23.5% 17.6%
VL, [95] Conventional IVM 60.6%a 55.0%a 27.3%a
2009 PMC-ECM, PDE-I 81.6%a 67.5%a 55.6%a
SC, [96]
2015
PMC-PDE-I 50.2% 68.3% 30.5%
Novel IVM systems
GPT, [97] Cumulus-denuded
1998 wo EGF 33.9%b 53.8% 42.8%
w EGF 64.3%b 72.7% 50%
Cumulus-intact
wo EGF 79% 45.6%a 95.2%
w EGF 81% 71.7%a 84.8%
BAI, [98] Conventional IVM 36.5.0%a 73.6% 85.7%
2011 IVM-EGF/AREG 75.5%a 71.8% 85.7%
SF, [99] Conventional IVM 48%c 31% 23%c 8%b
2017 PMC-CNP + IVM/ARE 70%c 53% 43%c 18%b
MA, [100] Standard-IVM 42%c 76% 38%c 40%
2018 AFF-IVM 34%c 73% 36%c 25%c
HFF-IVM 59% 80% 60% 42%
HFF-CGC-IVM 79%c 92% 71%c 65%c
PMC, prematuration culture;MII, metaphase II; FR, fertilization rate; CR, cleavage rate; BR, blastocyst rate; PDE-I, phosphodiesterase inhibitor; ECM,
extracellular matrix; w, with; wo, without; CNP, C-natriuretic peptide; P < 0.05a , P < 0.01b , P < 0.001c
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primary action of estrogen is on the pituitary and/or hypothal-
amus is still not clear.
The pituitary LH surge is controlled by gonadotropin-
releasing hormone (GnRH) secreted by hypothalamic GnRH
neurons. How the brain controls the pituitary gland and pitu-
itary gonadotropin secretion was not known until fairly recent-
ly. Early studies speculated that a neural factor controls repro-
duction [114]. Guillemin [115] and Schally [116] simulta-
neously discovered the neural factor, luteinizing hormone–
releasing hormone (LHRH), in 1971. This discovery
established the field of neuroendocrinology. The Nobel Prize
in Medicine was awarded to Guillemin, Schally, and Yaslow
in 1977. Yaslow developed the radioimmunoassay (RIA), a
method that utilizes radioactive isotopes to measure hormones
and other molecules. Insulin was measured for the first time
with the RIA method. A GnRH surge was identified in pitui-
tary stalk blood in rats [117] and primates [118] using the RIA
method. The mechanisms underlying the GnRH surge are still
not known. Estrogen is probably involved. Estrogen induces a
GnRH surge in the ewe [119].
The most important feature of the GnRH system is the
inherent pulsatility of GnRH neurons. Many years of research
have been devoted to this area [120–123]. GnRH neurons are
bipolar neuroendocrine cells that are located in the medial
basal hypothalamus. In primates, GnRH neuron cell bodies
are primarily located in the medial preoptic area of the hypo-
thalamus, while their axons are primarily found in the median
eminence [124]. GnRH is a decapeptide that is stored in
GnRH neuron vesicles. The vesicles are transported to the
GnRH neuron axon terminals where GnRH is released in a
pulsatile fashion into the portal vessels that surround the pitu-
itary gonadotropes. GnRH pulses, in the portal vessels, occur
every 30 min in rats [125] and every 60 min in primates. The
neural mechanism that controls pulsatile GnRH secretion is
still not clear [123]. GnRH neuron excitation-secretion cou-
plingmay be involved. IsolatedGnRH neurons in vitro release
GnRH in a pulsatile fashion [126]. GnRH neurons in vivo
generate periodic electrical bursts [127]. Estrogen [128, 129]
is probably involved, and GnRH neuron ion channels [130,
131] may have a role. Secreted GnRH binds the GnRH recep-
tors on the pituitary gonadotropes which stimulates cAMP
production. This results in increased intracellular calcium
which causes the release of LH and FSH. LH and FSH are
released into the peripheral circulation in a pulsatile fashion in
sheep and rats [132, 133], primates [134], women [135, 136],
and men [137]. LH is transported to the ovary where it binds
mural granulosa cell LH receptors.
LH Receptor
The mid-cycle LH surge in humans and animals activates the
luteinizing hormone receptor (LHR) also referred to as the
luteinizing hormone/choriogonadotropin receptor (LHCGR).
LHR is primarily expressed in the mural granulosa cells of the
ovarian follicle. The biological actions of LH, required for
oocyte maturation, ovulation, and corpus luteal function, in
the ovarian follicle are mediated by LHR which is coupled
to Gs, the G protein that activates adenylate cyclase and
cAMP. This results in an elevation of follicle cAMP levels
which affects multiple follicle LH signaling pathway mole-
cules that ultimately activate the maturation promoting factor
(MPF) in the oocyte which induces oocyte maturation, re-
sumption of meiosis, and the first meiotic division.
LH receptors belong to the rhodopsin/β2-adrenergic recep-
tor subfamily A of G protein–coupled receptors (GPCR). The
LH receptor is a seven-transmembrane domain cell surface
protein [138–141]. The human LH/hCG receptor was cloned
in 1995 [142]. It is composed of 701 amino acids, 333 amino
acids form the seven transmembrane domain segments, and
341 amino acids form the large extracellular domain. The
extracellular domain is the hormone-binding domain. LH
binds the LH receptor extracellular domain causing a confor-
mational change in Gsα resulting in replacement of GDP with
GTP. The GTPα unit activates adenylate cyclase which con-
verts ATP to cAMP [143–145]. LH receptors are expressed
exclusively in mural granulosa cells (GCs), and almost no
expression is found in cumulus cells (CCs) or the oocyte in
rats and mice [146–148].
LH receptor mRNA expression in mural granulosa cells is
regulated during the ovarian cycle. Peng et al. found that LH
receptor expression is up and downregulated during the ovar-
ian cycle [149]. In unstimulated rats, LH receptor mRNA
expression is not detectable in GC and cumulus granulosa
cells. In human menopausal gonadotropin (HMG)–stimulated
rats, LH receptor mRNA expression is highest in mural GC in
preovulatory follicles and is undetectable in CCs. Post-HCG,
LH receptor expression in mural granulosa cells (mGCs) de-
creases markedly and again increases in the corpus luteum.
The LH surge paradoxically downregulates LH receptor ex-
pression in preovulatory follicles [150–155].
The LH surge activates mGC LH receptors, which results
in a dramatic increase in follicle cAMP production.
Approximately 10,000 LH receptors are expressed in each
rat GC in preovulatory follicles [156]. Activation of LH re-
ceptors causes a 200-fold increase in cAMP levels in mural
GCs, which is referred to as the preovulatory cAMP spike
[157]. The cAMP spike transmits the LH signal to the cumu-
lus cells and the oocyte via multiple signaling pathways.
LHR mutations cause follicle development abnormalities
and infertility in animals and humans. LHR mutations in mice
cause an increase in antral follicles and they lack preovulatory
follicles which results in anovulation and infertility. Lei et al.
generated LH receptor knockout mice [158]. They are infer-
tile, the internal and external genitalia are severely underde-
veloped, the ovaries are small, and the ovarian follicles arrest
at the antral follicle stage. Zang et al. also generated LH
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receptor knockout mice [159]. The null mice are infertile, the
ovaries are small, and the ovarian follicles grow only to the
early antral stage. These studies suggest that LH is required for
the development of a dominant preovulatory follicle. Ovarian
follicle growth and development beyond the early antral stage
require some LH activation of the LH receptor.
In humans, LHR is primarily expressed in ovarian follicle
granulosa cells [25]. Similar to animals, LH receptor expres-
sion is highest in mGCs in preovulatory follicles. LH receptor
GC mRNA expression is 10-fold higher in preovulatory folli-
cles compared with small antral follicles [26, 27]. LHR ex-
pression is suppressed by the LH surge. The LH surge
downregulates GC LH receptor expression in preovulatory
follicles in women [28, 29]. The mid-cycle LH surge activates
mural GCLH receptors which activates adenylate cyclase [30]
and increases follicle cAMP levels (Fig. 2).
Mutations of LHR cause ovarian follicle development
abnormalities and infertility in women. Women with LHR
mutations experience amenorrhea, lack preovulatory folli-
cles, do not respond to exogenous HCG, and are infertile
[160]. Toledo et al. in 1996 reported a LHR mutation case
in a 21-year-old with 46XX primary amenorrhea, normal
secondary sexual development, and infertility [161].
Ovary size was normal on ultrasound. Histologic analysis
of an ovarian biopsy revealed primordial follicles, pre-
antral follicles, and antral follicles. No preovulatory folli-
cles were seen. DNA analysis of the LHR gene revealed a
single nucleotide change (guanine to cytidine at position
1787). This caused a substitution of a proline for an ala-
nine in the LH receptor. Human embryonic kidney cells,
transfected with the mutant LH receptor gene, did not
respond to HCG.
Latronica et al. reported a 40-year-old with irregular men-
strual cycles, normal menarche and pubarche, and infertility
[162]. The ovaries were normal size on pelvic ultrasound, the
FSH level ranged from 5 to 17 IU/l, the serum estradiol level
was < 50 pg/ml, total testosterone was normal, and karyotype
was 46XX. A six-nucleotide deletion in the LH receptor gene
resulted in deletion of leucine and valine. Cells transfected
with the mutated LHR cDNA revealed reduced LHR expres-
sion and reduced (1.5- vs. 30-fold in wild-type transfected
cells) stimulation of cAMP in response to HCG. These studies
show that LHR mutations cause anovulation and infertility.
These studies suggest that human early follicle development
is primarily FSH dependent, while preovulatory follicle devel-
opment requires LH. LHR may be abnormal in PCOS. LHR
mRNA is overexpressed in GC and theca cells in women with
PCOS when compared with normal controls [163].
The LHR mRNA expression in cumulus cells (CCs) may
predict oocyte quality. Yang et al. studied LHR mRNA ex-
pression in cumulus cells from 35 PCOS women who
underwent 50 IVM cycles [31]. Patients were given HCG
10,000 IU on cycle days 7 and 13, and oocytes were retrieved
36 h post-HCG. Cumulus-oocyte complexes (COCs) were
separated into 3 groups: dispersed CCs (group A), compacted
CCs (group B), and sparse CCs (group C). Dispersed CCs
were enclosed by an expanded CC and 1–2 corona cell layers,
compacted CCs contained 4–5 corona cell layers, and sparse
CCs had few coronal cells. COCswere cultured in IVMmedia






































Fig. 2 Human model of LH regulation of oocyte meiotic maturation. The
LH signal begins with mid-cycle LH activation of the mural granulosa
cell LH receptor. The LH signal rapidly suppresses CNP/NPR2, activates
the EGF/EGFR network, and inhibits gap junction activity. This reduces
follicle and oocyte cGMP levels, activates oocytes phosphodiesterases,
reduces oocyte cAMP levels, and activates the oocyte maturation promot-
ing factor (MPF). The MPF initiates resumption of meiosis by protein
phosphorylation of downstream proteins. The spindle assembly
checkpoint (SAC) proteins are activated at the kinetochore to induce
spindle formation and alignment. CDC20 activates the anaphase-
promoting complex (APC) which initiates the transition from metaphase
to anaphase by degrading securin releasing separase which degrades
cohesin. This frees chromosomes to segregate to opposite poles. The first
meiotic division is completed and the mature metaphase II oocyte remains
arrested until fertilization. +, activation or stimulation; −, inhibition
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and EGF for 24, 48, and 72 h. MII oocytes were inseminated
by ICSI; embryos were grown to days 5 and 6. IVM cycles
resulted in embryo transfers on day 6. CCs were collected
from the GV-staged oocytes, mRNA was extracted, and RT-
PCR for LHR, FSH receptor, and EGF receptor was per-
formed. The MII rate (Grp A-24h-70%, 48h-80%, 74h-
85%), blastocyst rate (A-40%, B-23%, C-23%), and CC LH
receptor mRNA expression levels were higher in group A than
groups B and C. The study concluded that oocytes from
expanded/dispersed CCs with high CC LH receptor mRNA
expression levels have better oocyte quality compared with
oocytes from unexpanded CCs with low LHR mRNA levels.
Regan et al. studied LHRmRNA expression density in 327
ovarian follicles from young and old patients treated with IVF
[29]. Granulosa cell LH receptor density was measured by
immunofluorescence from GCs retrieved after standard con-
trolled ovarian hyperstimulation. GC LHR density was in-
creased in young women compared with older women.
Higher live birth rates were found in young women with high
GC LHR density compared with older women with lower GC
LHR density. They also found that the LH surge–induced
downregulation of the LH receptor was evident mostly in
the larger follicles in young women. LHR downregulation
was not observed in follicles from older women. This sug-
gested to the authors that large follicles are more receptive to
the LH surge than smaller follicles since they downregulated
appropriately. This may indicate a GC dysfunction in small
follicles and follicles in older women. Also, the FSH dose
used for IVF stimulation was not associated with GC LHR
expression levels which suggests that other factors other than
gonadotropins regulate GC LHR expression during follicular
development. The authors concluded that high GC LH recep-
tor density and normal downregulation of the GC LH receptor
by the LH surge which is primarily found in preovulatory
dominant follicles are associated with oocyte quality.
Maman et al. found higher CC LHR mRNA expression in
MII oocytes compared with MI and GV oocytes; however,
higher LHR expression was not associated with higher fertil-
ization rates [32]. Huang et al. found that LHR CC mRNA
expression was not associated with a higher pregnancy rate
[33]. Whether high or low LHR mRNA expression in CCs is
associated with oocyte and embryo quality is not clear.
Follicle C-natriuretic Peptide and Natriuretic
Peptide Receptor 2
The first target of the LH signal in the follicle compartment is
the CNP/NPR2 system. LH suppresses the CNP/NPR2 sys-
tem and within minutes reduces cGMP follicle levels. This
ultimately leads to activation of the oocytematuration promot-
ing factor (MPF) which initiates resumption of meiosis and
chromosome segregation. The CNP/NPR2 system is the
major inhibitor of oocyte meiosis progression in the ovarian
follicle. The first clue that ovarian follicle somatic cells ex-
press an inhibitor that prevents meiotic progression came
when Pincus and Enzman in 1935 observed spontaneous oo-
cyte maturation within 1–2 h in vitro at the time oocytes were
separated from ovarian follicle somatic cells [164]. This phe-
nomenon occurs in mouse, sheep, cow, pig, monkey, and hu-
man oocytes [165].
Initial studies suggested that the follicle factor responsible
for oocyte meiotic arrest was cAMP [166–168]. Later studies
showed that cAMP produced by the oocyte, not cAMP from
the follicle, was the major inhibitor of oocyte meiotic arrest.
Mehlmann et al. injected mouse oocytes with antibodies
against stimulatory G protein (Gs) which stimulates oocyte
adenylyl cyclase and cAMP production. This caused resump-
tion of meiosis, 80% of the injected oocytes developed GVBD
showing that oocyte Gs is required for meiotic arrest [169].
Horner et al. showed that oocyte GPR3 activates oocyte
adenylyl cyclase (AC3) which produces cAMP in the oocyte
[170]. Later, Mehlmann et al. showed that the oocyte Gs is
linked to the oocyte receptor G protein–coupled receptor 3
(GPR3) which is required for meiotic arrest in mice [171]
and humans [78].
cGMP is the major factor in the follicle responsible for
oocyte meiotic arrest [9]. Norris et al. found that reducing
oocyte cGMP levels increased the activity of oocyte phospho-
diesterase 3A (PDE3A) and lowered levels of oocyte cAMP
which induced resumption of meiosis [172]. They also found
that blocking follicle gap junctions reduced oocyte cGMP.
They concluded that cGMP produced by ovarian follicle so-
matic cells enters the oocyte through gap junctions and in-
hibits PDE3A activity which allows high levels of cAMP to
accumulate in the oocyte. High oocyte cAMP levels trigger
resumption of meiosis. How is cGMP produced in the ovarian
follicle compartment?
C-natriuretic peptide (CNP), also called natriuretic peptide
precursor C (NPPC), and its receptor guanylyl cyclase natri-
uretic peptide receptor 2 (NPR2) produce cGMP in the ovar-
ian follicle compartment. CNP and NPR2 are highly
expressed and regulated in ovarian follicles during the rat
estrus cycle [173]. In 2010, Zhang et al. showed that CNP
mRNA expression was 10-fold higher in mural GCs com-
pared with CCs, and NPR2 mRNA expression was 2-fold
higher in CCs compared with mGCs [174]. CNP increased
oocyte cGMP levels in the follicle which inhibited meiotic
resumption. They also studied the role of oocyte-secreted fac-
tors (OSFs) on the follicular compartment. They found that
bone morphogenetic peptide 15 (BMP15) combined with
growth differentiation factor 9 (GDF9) increased CC NPR2
mRNA expression. This suggested that BMP15 and GDF9
primarily inhibit meiotic progression.
Based on these findings, the authors proposed a model for
oocyte meiotic arrest. Mural GC CNP activates CC NPR2
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which increases cGMP production in the follicular compart-
ment. Follicle cGMP diffuses through follicle/oocyte gap
junctions into the oocyte. Oocyte cGMP inhibits oocyte
PDE3A activity which increases oocyte cAMP. High oocyte
cAMP levels inhibit resumption of meiosis. Genetic studies
support this model. NPR2 mutant mice are infertile due to
premature resumption of meiosis caused by a lack of follicle
cell cGMP production which results in oocyte fragmentation
and poor embryo development [175, 176]. Humans with
NPR2 mutations develop acromesomelic dysplasia,
Marateaux type (AMDM) [177]. Infertility has not been de-
scribed in these patients.
LH exposure inhibits the CNP/NPR2 system which in-
duces oocyte meiotic resumption in preovulatory follicles.
LH reduces cGMP levels very rapidly in the mural GC, CC,
and oocyte. Time-lapse recordings of cGMP levels in mouse
follicles showed a decrease in cGMP levels in mural GCs
within 1 min of LH exposure, in CC within 5 min, and in
oocytes within 10 min [178]. LH reduced NPR2 activity in
mural GCs and CCs within 3 h of LH exposure by dephos-
phorylation, and NPR2 protein levels did not change. LH also
reduced CNP levels within 2 h of LH exposure [17]. How the
LH deactivates NPR2 is not clear. One possible mechanism is
that LH activates EGF/EGFR which inhibits NPR2. EGF re-
ceptor was activated within 15 min after LH application [179]
and resulted in reduced follicle cGMP levels [180].
In humans, the ovarian follicle CNP/NPR2 system has
not been well studied. One paper showed that LH reduces
CNP levels in human ovarian follicular fluid [16], and one
paper found NPR2 mRNA expression in human mural
GCs [34] (Fig. 2).
Epidermal Growth Factor Network
The second target of the LH signal is the ovarian follicle
EGF network. The activated EGF network transmits the
LH signal from the mural granulosa cells (mGCs) to the
oocyte in preovulatory follicles. The activated EGF net-
work inhibits the CNP/NPR2 system and gap junctions
reducing follicle and oocyte cGMP. This occurs via the
EGF receptor which is highly expressed in follicle cumu-
lus cells. cGMP is the molecule that transmits the LH
signal from the follicle to the oocyte.
EGF-like protein (EGF-LP) growth factors stimulate oo-
cyte meiotic maturation and cumulus cell expansion [36,
181]. The first evidence that EGF regulates these processes
came in the 1980s [182, 183]. Recently, Park et al. showed
that LH, within 3 h, stimulates production of epidermal
growth factor-like protein (EGF-LP) family members:
amphiregulin (AREG), epiregulin (EPI), and beta-cellulin
(BTC) in mice ovaries [184]. EGF-LP expression was restrict-
ed to mural GCs in preovulatory follicles. EGF-LP stimulated
oocyte meiotic maturation within 4 h of exposure to AREG
and EPI as GVBD was observed in 100% of the oocytes in
preovulatory follicles. EGF-LP also stimulated cumulus cell
expansion within 8 to 12 h of exposure to AREG, EPI, or
BTC. Cumulus cell expansion genes were upregulated.
Hyaluronan synthase 2 (HAS2), prostaglandin-endoperoxide
synthase 2 (Ptgs2), and tumor necrosis factor alpha–induced
protein 6 (Tnfaip) mRNA expression levels increased within
3 h of exposure to EPI, AREG, and BTC. LH stimulates pro-
duction of AREG, EPI, and BTC via p38 mitogen–activated
protein kinase (MAPK) [185, 186]. In null AREG and EREG
mice, meiotic resumption is reduced [187].
Activation of the EGF receptor (EGFR) is required for
oocyte meiotic resumption [188] and cumulus cell expan-
sion. EGF receptors are members of the tyrosine kinase
receptor (TKR) family that includes ErbB1, ErbB2,
ErbB3, and ErbB4 [189]. EGF tyrosine kinase receptors
are single-transmembrane domain receptors that regulate
cellular proliferation. EGF binding sites were first identi-
fied on rat GCs in secondary ovarian follicles in 1986
[190]. The highest EGFR mRNA expression levels are
in CCs [181]. LH causes EGF receptor (EGFR) phosphor-
ylation within 3 h of exposure [184]. EGFR activation is
required for LH action. EGFR inhibitors block LH-
induced oocyte meiotic resumption and CC expansion.
EGFR signals via extracellular signal–regulated kinases
1 and 2 (ERK1/2) [191, 192]. Granulosa cell–specific
EGFR null mice fail to resume meiosis [193].
The LH-activated EGF network targets the CNP/NPR2
system and follicle/oocyte gap junctions. The EGF network
inhibits CNP/NPR2 production of cGMP and suppresses gap
junction activity. LH-activated EGFR reduces CNP mRNA
expression levels in granulosa cells [176], and cGMP levels
in the follicle and oocyte. Reduced oocyte cGMP levels acti-
vate oocyte PDE which reduces oocyte cAMP levels. This
activates the oocyte maturation promoting factor (MPF)
which initiates resumption of meiosis [180, 194].
The EGF system is found in the human follicle [36].
The human primordial follicle does not express EGF or
EGFR [37]. Maximum EGF and EGFR expression occurs
in preovulatory follicles [38]. EGF is expressed in human
preovulatory follicle follicular fluid (FF) [39]. Reeka et al.
failed to detect EGF in human FF, but found EGF in GCs
[40]. Zamah et al. found EGFR mRNA expression in hu-
man GCs from IVF patients [35].
LH increases production of EGF-LP in human GCs and
CCs (Fig. 2) [41, 42]. AREG mRNA and protein are
expressed in human GCs [41]. AREG is the most abundant
EGF-like growth factor in follicular fluid aspirated at oocyte
retrieval in IVF patients stimulated with gonadotropins.
Rimon et al. reported a 286-fold increase in AREG expression
in GC from IVF patients [43]. Whether EGF-LP suppresses
CNP/NPR2 and inhibits gap junctions resulting in oocyte
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meiotic resumption is not known. One study found that LH
reduces CNP levels in human FF [35].
Mixed results have been found in studies investigating the
association between EGF molecules and oocyte quality.
Feuerstein et al. found a positive correlation between CC
AREG mRNA expression and blastocyst rate [44]. Huang
et al. found that high CC AREG mRNA expression from
MII oocytes was associated with pregnancy rate [33]. Zamah
et al. found that AREG levels from FF correlated with oocyte
maturation rate [35]. Hoffman et al. found that human EGF FF
levels were inversely correlated with oocyte maturation [45].
Inoue et al. found that FF AREG levels were inversely corre-
lated to fertilization rate and was not correlated with embryo
quality [46]. A reliable EGF network oocyte quality biomark-
er has not been identified.
Gap Junction Communication
The third major target of the LH signal is the follicle/oocyte
gap junction. Gap junction channels allow direct communica-
tion between cells. They allow ions and molecules to pass
from the cytoplasm of one cell to the cytoplasm of the other,
thereby coupling the cells metabolically and electrically.
Studies have demonstrated that small fluorescent dye mole-
cules injected into one cell can pass into adjacent cells, pro-
vided the molecules are smaller than 1000 Da. This suggests a
gap junction channel diameter of 1.5 nm so cells can share
small molecules like ions, nucleotides, and amino acids, but
not large molecules like proteins or nucleic acids. The molec-
ular mass of cGMP is 345.2 and cAMP 507 Da. Gap junctions
are formed from connexons which are formed from
connexins. Several distinct connexins have been identified.
Connexins are named by their molecular weights. Connexin
43 has a molecular weight of 43 kDa. Gap junction channels
behave like conventional gated ion channels. They flip be-
tween open and closed states, switching rapidly within sec-
onds. Gap junctions regulate hearing, cardiac and neural func-
tion, liver function, and ovarian folliculogenesis and oogene-
sis [195, 196].
Gap junctions are present between mural granulosa cells
and cumulus cells [166], and between cumulus cells and oo-
cytes [197]. Connexins are expressed in ovarian follicles [198,
199]. Connexin 43 and 37 are the primary functional
connexins in the ovarian follicle. Cx43 is the major connexin
expressed in rat granulosa/cumulus cells [200]. Cx37 is pri-
marily expressed in the oocyte [201]. Gap junctions regulate
meiotic arrest and resumption [198]. CNP/NPR2 produces
cGMP in cumulus cells which diffuses into oocytes through
Cx43 gap junctions which elevates oocyte cGMP. This main-
tains oocyte meiotic arrest [202].
LH disrupts gap junction (GJ) communication between the
follicle somatic cells and oocyte which induces resumption of
meiosis. Initial gap junction studies found that loss of CC gap
junctions induced GVBD in rat oocytes [203, 204]. LH closes
follicle GJs [205, 206] and oocyte GJs [207]. LH inhibits rat
gap junction activity via MAPK phosphorylation [207] of
Cx43 and also reduces Cx43 protein levels [208]. The activat-
ed EGF network also closes cumulus cell and oocyte gap
junctions [180]. AREG activates EGF receptor which closes
follicle gap junctions. This prevents transport of cGMP from
the follicle somatic cells to the oocyte which induces resump-
tion of meiosis [172]. In porcine IVM conditions, LH closes
connexin 43 gap junctions [209]. Mice lacking connexin 37
lack mature Graafian follicles, and the oocytes are arrested at
the early antral stage, fail to grow, fail to ovulate, and develop
inappropriate corpus lutea [210, 211].
Gap junctions regulate human ovarian folliculogenesis
(Fig. 2) [47]. Human ovarian follicles express 15 connexins,
but only Cx43 and Cx37 form gap junctions [48, 49]. Cx43 is
the major gap junction connexin in human cumulus cells [49].
Human gap junctions are regulated by cAMP [50]. BMP15
reduces Cx43 expression and gap junction activity in human
granulosa cell lines and granulosa cells [51]. Whether LH
closes human follicle/oocyte gap junction activity is not
known. We found no studies addressing this question.
Cumulus cell mRNA expression studies suggest Cx43may
be a potential biomarker of human oocyte quality. Feuerstein
et al. found that Cx43 was associated with improved oocyte
quality [52]. Wang et al. found higher live birth rates in oo-
cytes with high CC Cx43 mRNA levels [49]. Low CC Cx43
expression was found in low responders [53]. Reduced ex-
pression of Cx43 at oocyte retrieval was associated with im-
proved oocyte quality [54]. Double trigger with GnRH agonist
and HCG reduced Cx43 mRNACC expression and improved
oocyte and embryo quality [55]. It is not clear whether in-
creased or decreased Cx43 CC mRNA 43 expression is asso-
ciated with oocyte quality.
Oocyte-Secreted Growth Factors: BMP15
and GDF9
The major oocyte-secreted growth factors studied so far are
BMP15 and GDF9. Whether oocyte BMP15 and GDF9 are
targets of the LH signal during oocyte meiotic maturation in
animals or humans is not known. It is well established that
pituitary gonadotropins regulate ovarian folliculogenesis and
oocyte quality [212, 213]. Recent work suggests that the oo-
cyte regulates folliculogenesis [214–219] and oocyte quality
[220, 221]. Oocyte-secreted factors (OSFs), bone morphoge-
netic protein 15 (BMP15) and growth differentiation factor 9
(GDF9), are important regulators of ovarian follicle develop-
ment [222, 223]. They are exclusively expressed in the oocyte,
are present in all stages of follicular growth [224], and may
have a role in human oocyte maturation. Recently, other OSFs
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have been identified. Oocyte interleukin-7 (IL-7) was found to
possibly have a role in human oocyte maturation [225].
BMP15 and GDF9 regulate animal and human ovarian
folliculogenesis. Initial studies, 50 years ago, found that pre-
mature luteinization of the rabbit ovarian follicle occurs when
the oocyte is removed from the follicle. This suggested that an
oocyte-secreted factor (OSF) prevents luteinization. The au-
thors proposed the concept that the oocyte controls follicle
somatic cell processes [226]. Mouse genetic studies showed
that GDF9 is required for normal ovarian follicle development
[227]. GDF9 null mice ovarian follicles do not progress be-
yond the primary follicle stage, which results in infertility.
During the last decade, studies in animals showed that
GDF9 and BMP15 are involved in cumulus cell expansion
[228, 229] and oocyte quality [72, 221, 230].
BMP15 and GDF9 are members of the transforming
growth factor-beta (TGF-β) superfamily, a structurally
conserved group of proteins with at least 35 members
[231]. The members of the superfamily are classified into
subfamil ies. They include the TGF-β subfamily
(TGF-β1-β3); the bone morphogenetic (BMP) subfamily
is the largest with 20 members, the growth differentiation
factor (GDF) subfamily with 9 members, the activin/
inhibin subfamily, the glial cell–derived neurotrophic fac-
tor (GDNF) subfamily, and anti-Mullerian hormone. GDF9
was initially discovered in 1993 [232]. The TGF-β super-
family is composed of growth factors that regulate repro-
duction, embryo development, and tumor growth [233].
The TGF-β superfamily members act by binding two types
of serine/threonine kinase cell surface receptors called types I
and II. Seven type I and five type II receptors have been
identified. BMP15 and GDF9 bind several receptors including
the serine/threonine kinase receptor type II bone morphoge-
netic receptor type-2 (BMPR2) [234], bone morphogenetic
receptor type-IB (BMPR1B) also known as activin receptor–
like kinase (ALK6) and bone morphogenetic receptor type-IA
(BMPR1A) also known as ALK3. BMP15 and GDF9 primar-
ily bind BMPR1Bwhich is the major TGF-β receptor in ovar-
ian follicles [58, 222, 235, 236]. GDF9 and BMP15 signal
through SMAD transcr ip t ion fac tors ( fus ion of
Caenorhabditis elegans Sma genes and the Drosophila
Mad,Mothers against decapentaplegic) [237] to regulate gran-
ulosa cell function in animals and humans [58].
GDF9
Growth differentiation factor 9 (GDF9) is an oocyte-derived
growth factor [238] required for folliculogenesis and oogene-
sis. It is a protein in the TGFβ superfamily, composed of 454
amino acids with a molecular weight of 53.4 kDa. GDF9
controls follicle growth by stimulating ovarian follicle granu-
losa cell proliferation at all stages of follicle development
[239, 240]. It stimulates granulosa cell proliferation [241] by
both increasing GC FSH receptor expression [242] and
preventing GC apoptosis [243].
GDF9 is required for oogenesis. GDF9 null mice are infer-
tile due to severe follicle and oocyte abnormalities [227]. The
ovaries are small, and primordial and primary follicles never
develop more than only 1 layer of granulosa cells. Follicular
development never progresses beyond this early stage. The
ability of the granulosa cells to proliferate is severely limited.
The primary follicle oocytes are enlarged (70-μm diameter);
they resemble antral follicle oocytes. Electron microscopy oo-
cyte studies found perinuclear organelle aggregation, abnor-
mal Golgi complexes, and failure to form cortical granules
[244]. This study demonstrated for the first time that the oo-
cyte controls the progression of follicular development.
GDF9 promotes cumulus cell expansion during pre-
ovulatory follicle development. LH stimulates CC expan-
sion which is essential for the acquisition of oocyte qual-
ity [221]. The factors that control CC expansion are still
not known. GDF9 regulates numerous CC functions that
are involved in CC expansion [245]. GDF9 induces CC
expansion genes including pentraxin (Ptx3), hyaluronan
synthase 2 (Has2), tumor necrosis factor alpha–induced
protein 6 (Tnfaip6), and prostaglandin-endoperoxide syn-
thase 2 (Ptgs2) [246]. GDF9 also inhibits granulosa cell
LH receptor mRNA expression [246]. RNA interference
studies in mice decrease oocyte GDF9 protein expression,
prevent CC expansion, and reduce Has2 and Pgs2 mRNA
expression [247]. In addition, GDF9 regulates CC choles-
terol biosynthesis [248] and glycolysis [249] which is re-
quired to support the metabolic activity during CC expan-
sion. SMAD mice knockouts demonstrate that SMAD 2,
3, and 4 are required for CC expansion [250, 251]. Recent
studies suggest that BMP15:GDF9 mouse and human het-
erodimers are potent regulators of CC expansion [252].
These studies support the hypothesis that GDF9 regulates
CC expansion.
The role of GDF9 in human folliculogenesis, cumulus cell
expansion, and oocyte meiotic maturation is not clear. GDF9
is expressed in human oocytes [25, 61, 62]. Aaltonen et al.
studied GDF9 expression in ovarian biopsies from women
under the age of 35 [61]. They found GDF9 mRNA expres-
sion in primary oocytes. Primordial oocytes did not express
GDF9. Because they did not find antral follicles or preovula-
tory follicles in their biopsy specimens, they were not able to
study GDF9 in these later stages. GDF9 stimulates human
granulosa cell (GC) proliferation [63, 64]. GDF9 stimulates
activin signaling [62] and inhibits follistatin [65] in preovula-
tory luteinized GC from women undergoing IVF. GDF8
downregulates Ptx3, a cumulus cell expansion gene, in human
GC [66, 67]. Huang et al. reported the first human study on
GDF9 regulation of human-luteinized GC cycle progression
[68]. GDF9 upregulates both cyclin D1 and E mRNA and
protein via ERK42/44 and SMAD3.
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Human genetic studies suggest that GDF9 regulates human
folliculogenesis and oocyte development. GDF9 mutations
cause premature ovarian insufficiency (POI). Seven GDF9
human mutations have been identified that cause POI
[253–256]. GDF9 mutations may cause diminished ovarian
reserve [256]. Oocyte GDF9 expression is reduced in PCOS
patients [69–71]. This suggests that low GDF9 expression
may block antral follicle development, the main follicle ab-
normality found in PCOS.
GDF9 targets including HAS2, TNFA1P6, PTGS2, and
gremlin 1 are potential biomarkers of oocyte quality [246,
257, 258]. In humans, CC HAS2, PTGS2, and gremlin
mRNA expression correlates with oocyte quality [259,
260]. Feuerstein et al. found that CC PTGS mRNA is
associated with oocyte maturation [44]. Gode et al. found
that increased FF GDF9 protein levels correlated with
improved oocyte maturation and embryo quality [261].
These studies suggest that CC expansion genes and
GDF9 in FF are associated with oocyte quality.
The GDF9 receptor, BMPRII, is also a potential bio-
marker of oocyte quality. Regan et al. studied granulosa
cell BMPR1B mRNA density in young and old women
treated with IVF [29]. In young women, no correlation
was found between GC BMPR1B density and GC LHR
density (R2 = .078); as expected, GC BMPPR1B density
did not increase and was downregulated, as LHR density
increased. In older women, BMPR1B density increased as
LHR density increased (R2 = 0.87; p = 0.004). The authors
concluded that normal downregulation of GC BMPR1B is
associated with oocyte quality.
BMP15
Bone morphogenetic protein (BMP15) is a 392-amino acid
dimeric protein in the TGF-β super family, exclusively
expressed in the oocyte. BMP15 is expressed in the oocyte
throughout follicular development. It binds granulosa cell
TGF-β receptors and activates SMAD transcription factors
that regulate gene expression. BMP15 stimulates
folliculogenesis, cumulus cell expansion, oogenesis, and oo-
cyte maturation and controls ovulation number and oocyte
developmental competence. BMP15 human mutations cause
ovarian dysgenesis and premature ovarian failure.
BMP15 stimulates proliferation of ovarian follicle GCs
[236, 242, 262], stimulates cumulus cell expansion [230,
263], and inhibits ovarian follicle steroidogenesis. In mice,
BMP15 regulates CC expansion via SMAD 2/3 stimulation
of gene transcription [250, 264, 265], stimulation of CC
EGFR expression [266], and inhibition of CC apoptosis [267].
BMP15 promotes oocyte meiotic arrest by increasing fol-
licle cGMP levels by increasing follicle CNP/NPR2 activity,
by increasing NPR2 gene expression [268], and by modulat-
ing gap junction activity [51]. In preovulatory follicles,
BMP15 inhibits FSH receptor expression and reduces proges-
terone and estrogen production [269].
Sheep with homozygous BMP15 mutations [270] are
infertile and develop streak gonads, and folliculogenesis
is blocked at the primary follicle stage [271, 272].
Ovulation rates are increased in sheep with heterozygous
BMP15 mutations [270].
The role of BMPs in human folliculogenesis and oogenesis
is still unclear [273]. Human ovarian follicles express BMPs
and BMP receptors. BMP15 protein and mRNA are expressed
in oocytes and granulosa cells in fetuses and young women
[73]. BMP6 and BMP15 are the most highly expressed BMPs
in pre-antral human follicles. GDF9, BMPR2, and SMAD3–4
are also expressed in human pre-antral follicles [56]. BMP2,
BMP4, BMP7, BMP15, GDF8, and GDF9 are present in hu-
man pre-antral follicle follicular fluid (FF). BMP4, BMP5,
BMP6, BMP7, and BMP8 are also expressed in human GCs
[74]. BMPRII is the most highly expressed type II receptor in
cumulus cells [57]. ALK1 through ALK7 are also expressed
primarily in pre-antral and antral follicles [56].
How BMP15 regulates ovarian folliculogenesis and oocyte
maturation in humans remains unclear. BMP15 suppresses
ovarian follicle steroidogenesis and gap junction activity.
BMP15 prevents luteinization by suppressing GC progesterone
production. BMP15 and GDF9 decrease GC progesterone pro-
duction by inhibiting StAR expression [75, 76]. BMP15,
BMP7, and BMP4 regulate Cx43 expression [51, 274].
cAMP enhances BMP15-regulated SMAD 1/5/8 signaling in
human granulosa cells, suggesting communication between the
follicle cAMP system and BMP15/SMAD [59]. BMP15 and
GDF9 augment FSH/cAMP stimulation of aromatase mRNA
expression in human cumulus cells via SMAD 2/3 [60].
Human BMP15 mutations were first reported in 2004 in
two Italian sisters with premature ovarian insufficiency (POI),
ovarian dysgenesis, and a granulosa cell proliferation deficien-
cy [275]. Over 1236 cases of POI associated with BMP15
mutations have been described. The risk of a BMP15mutation
is 10× higher in POI patients [276].
BMP15 is a potential biomarker of human oocyte quality.
Higher oocyte maturation rates were found in oocytes from
follicles with high BMP15 follicular fluid (FF) levels [77,
277]. In IVF poor responders, high BMP15 FF levels are
associated with higher fertilization rates, cleavage rate, and
good-quality blastocyst compared with low BMP15 FF levels
[77]. Li et al. studied 196 infertile women and 2426 COCs.
Increased BMP15 and GDF9 mRNA levels in CC correlated
with oocyte maturation, fertilization, and embryo quality [72].
Higher oocyte quality was found in oocytes from follicles with
high cumulus cell BMP2 expression levels [278].
Dysregulation of activin receptor–like kinase 6 (ALK6) in
human GCs is correlated with decreased ovarian reserve
[28]. A BMP15 single nucleotide polymorphism is associated
with ovarian hyperstimulation [279].
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Oocyte Maturation Promoting Factor:
Cyclin-Dependent Kinase 1 and Cyclin B1
The major target of the LH signal in the oocyte is the matura-
tion promoting factor (MPF). The activated MPF initiates re-
sumption of meiosis in the preovulatory follicle. The MPF
complex has two components, a cyclin-dependent protein ki-
nase1 (CDK1), also known as cell division cycle protein 2
(Cdc2), and cyclin B [280]. TheMPF acts by phosphorylating
downstream proteins. Three of the major systems are the SAC
proteins, APC/C, and the securing-separase/cohesin proteins.
These cell cycle control proteins first appeared 1 billion years
ago and have been conserved in all eukaryotic species from
yeast to humans. The same cell cycle mechanisms that operate
in yeast and invertebrates also operate in humans.
Phosphorylation of these proteins by CDK1 induces cell cycle
progression and completion of the first and second meiotic
divisions. TheMPF and the other components of the cell cycle
machinery are not well characterized in human oocytes.
The MPF controls both the mitotic and meiotic cell cycles.
The cell cycle is the fundamental way bywhich cells grow and
divide. The cell cycle is divided into four distinct phases: M
phase, G1 phase, S phase, and G2 phase. During the M phase,
the cell divides by mitosis and cytokinesis. The G1 phase is
the gap between theM phase and S phase. During the S phase,
the DNA replicates. The G2 phase is the gap between the S
phase and M phase. The interphase is the period between one
M phase and the next M phase. During interphase, the cell
grows continuously. The duration of the M phase in an aver-
age eukaryotic cell is 1 h. The average cell cycle duration is
24 h. The early embryonic cell cycle duration in preimplanta-
tion human embryos is 12–24 h. The cell cycle is controlled
by a biochemical machine composed of proteins that duplicate
and divide the cell and its contents.
TheMPFwas purified from Xenopus eggs [281, 282] and
starfish oocytes [283]. The human CDK1 cDNA [284] and
protein sequence [285] were subsequently identified. CDK1
is composed of 297 amino acids. The molecular weight is
34 kDa. The crystal structure of CDK1 was recently report-
ed [286]. CDK1 is a serine/threonine-specific kinase acti-
vated by a cyclin partner. The CDK family is composed of
20 proteins divided into two major groups: cell cycle
(CDK1, 2, 3, 4, 6, 5, 14, 15, 16, 17, 18) and transcriptional
[7–13, 19, 20, and]. The cyclin family is composed of 30
proteins [287, 288]. CDK1 controls the cell cycle. Seventy-
five targets of CDK1 have been identified that regulate
many aspects of the mitotic cell cycle, including DNA rep-
lication and segregation, cell differentiation, cell polarity
and morphology, genome stability, transcription, and me-
tabolism [289]. CDK1 also regulates meiosis.
High oocyte cAMP levels prevent resumption of oocyte
meiosis. High oocyte cAMP levels are maintained by consti-
tutively active oocyte GPR3 receptors [8] and low oocyte
phosphodiesterase (PGE3A) activity maintained by high oo-
cyte cGMP levels which prevents hydrolysis of cAMP to
AMP [290]. The phosphodiesterase (PDE) superfamily is
composed of 11 PGE gene families [291]. PDE3A is highly
expressed in mouse oocytes [292]. Resumption of meiosis is
blocked in PDE3A knockout mice [293]. Mehlmann et al.
found that oocyte G protein–coupled receptor 3 (GPR3)
and GPR12 activate oocyte adenylate cyclase which in-
creases cAMP [169]. GPR3 is essential for meiotic arrest
in mice. GPR3 is expressed 14-fold higher in the oocyte
compared with follicular somatic cells. GPR3 knockout
mice undergo spontaneous oocyte nuclear maturation
[171], and mice lacking adenylyl cyclase-AC3 spontane-
ously resume meiosis progression [170].
High oocyte cAMP levels inhibit the MPF via activation of
oocyte phosphatases. The major MPF oocyte phosphatase in-
hibitors are WEE1B, CDC25, and CDC14A [11, 294].
CDC25A and CDC25B phosphatases inactivate Cdk1/
Cyclin B, which maintains oocyte meiosis arrest in mice
[295–297]. CDC14A phosphatase also inhibits CDK1 [298].
In vivo knockdown of WEE1B induces spontaneous resump-
tion of meiosis [299, 300].
The LH signal activates the MPF [301]. LH reduces follic-
ular oocyte GMP levels which activates oocyte PDE3A. This
in turn reduces oocyte cAMP levels. Low oocyte cAMP levels
inactivate oocyte phosphatases, WEE1B and CDC25 [302,
303], which dephosphorylate and activate oocyte CDK1
[18]. The activated CDK1-cyclin B complex phosphorylates
many downstream substrates including spindle assembly
checkpoint (SAC) proteins localized at chromosome kineto-
chores [304]. The primary SAC proteins include Mad1,
Mad2, Bub1, BubR1, Bub3, Mps1, and aurora B/C kinase.
Themain function of SAC proteins is to assure that each phase
of the cell cycle is completed prior to progressing to the next
phase, and to guide microtubule spindle attachment to the
kinetochores [305, 306]. SAC protein function is well studied
in mitosis while in meiosis their functions are less clear [307].
The primary target of the SAC is the anaphase-promoting
complex/cyclosome (APC/C) [308]. The APC/C is an ubiqui-
tin ligase that adds ubiquitins on target proteins which are
recognized and degraded by the proteasome. SAC proteins
Mad1, Mad2, and BubR1 inhibit the APC/C. SAC proteins
inhibit the APC/C from targeting securin (anaphase inhibitor)
and cyclin B [304], thereby preventing resumption of meiosis.
The activated APC/C-Cdc20 induces entry into anaphase and
chromosome segregation [307]. Separase is inactive when
bound to securin. At anaphase, the APC/C activated by
Cdc20 cleaves securin (anaphase inhibitor) which activates
separase. Activated separase cleaves the cohesin complex sub-
units which induces chromosome segregation.
In humans, the oocyte MPF complex is not well character-
ized [309]. CDK1 [25, 79, 80], CDC25 [25, 84], and WEE2
are expressed in human oocytes [80]. Sang et al. foundWEE2
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mutations in four women with fertilization failure [83]. The
age of the patients ranged from 27 to 37, the mean number of
oocytes retrieved per IVF cycle was 9, and the mean oocyte
maturation rate was 70%. All MII oocytes inseminated by
ICSI failed to fertilize. Sanger sequencing identified WEE2
mutations in all 4 women.
SAC proteins including Bub1B, Bub3, AURKA [25, 80,
82, 85–87], securin [82], and separase [88] are expressed in
human oocytes. Cohesin is a multi-subunit protein complex
made of four subunits. Four cohesin subunits are expressed in
fetal [89] and adult human oocytes [90]: SMC1β, SMC3,
REC8, STAG3. Tsutsumi et al. found an age-related decrease
of REC8 and SMC1β protein in prophase I–arrested oocytes
in women. This suggests that a decrease in oocyte cohesin
levels may cause human oocyte aneuploidy [91, 92]. STAG3
mutations may cause POI [310].
Oocyte Quality and IVM
One of the main clinical challenges facing assisted reproduc-
tive technology (ART) practitioners is the ability to select
developmentally competent eggs and viable embryos [311].
The major problem is the unknown nature of oocyte compe-
tence also referred to as oocyte quality. Oocyte quality is de-
fined as the ability of the oocyte to achieve meiotic and cyto-
plasmic maturation, fertilize, cleave, form a blastocyst, im-
plant, and develop an embryo to term [312]. A major task
for oocyte biologists is to find the oocyte mechanisms that
control oocyte competence. Oocyte competence is acquired
before and after the LH surge (Fig. 1). The development of
oocyte competence requires successful completion of nuclear
and cytoplasmic maturation [21]. Nuclear maturation is de-
fined by cell cycle progression and is easily identified by
microscopic visualization of the metaphase II oocyte. The
definition of cytoplasmic maturation is not clear [5]. What
are the oocyte nuclear and cytoplasmic cellular processes re-
sponsible for the acquisition of oocyte competence? What are
the oocyte genes and how many control oocyte competence?
Does LH signaling regulate oocyte competence? Can oocyte
competence be improved?
Developmentally competent oocytes are able to support
subsequent embryo development (Fig. 1). Oocytes progres-
sively acquire competence during oogenesis. Several key oo-
cyte nuclear and cytoplasmic processes regulate oocyte com-
petence. The primary factor responsible for oocyte compe-
tence is probably oocyte ploidy and an intact oocyte genome.
A mature oocyte must successfully complete two cellular di-
visions to become a mature healthy oocyte. During these cel-
lular divisions, a high percentage of human oocyte chromo-
somes segregate abnormally resulting in chromosome aneu-
ploidy. Oocyte aneuploidy is probably the major cause of
reduced oocyte quality. Human oocytes are prone to
aneuploidy. Over 25% of human oocytes are aneuploid com-
pared with rodents 1/200, flies 1/2000, and worms 1/100,000.
Many human blastocysts are aneuploid [313]. The major
cause of human oocyte aneuploidy is chromosome non-
disjunction [309, 314–317].
Approximately 40% of euploid embryos are not viable.
This suggests that factors other than oocyte ploidy regulate
oocyte competence. Other key oocyte nuclear processes in-
clude oocyte cell cycle mechanisms, oocyte spindle formation
[305, 318], oocyte epigenetic mechanisms [319], oocyte DNA
repair mechanisms, and oocyte meiotic maturation [12, 312].
Oocyte cytoplasmic processes include oocyte cytoplasmic
maturation [5, 320], bidirectional communication between
the oocyte and cumulus cells [101, 221, 321], oocyte mito-
chondria, oocyte maternal mRNA translation [322, 323], and
oocyte biomechanical properties [81]. During the last 10 years,
human oocyte gene expression studies have identified genes
that regulate oocyte competence.
Microarray studies of human oocytes suggest that over
10,000 genes are expressed in MII oocytes [324, 325]. In
an early microarray study, Bermudez et al. found 1361
genes expressed per oocyte in five MII-discarded oocytes
that failed to fertilize [326]. These genes are involved in
many oocyte cellular processes: cell cycle, cytoskeleton,
secretory, kinases, membrane receptors, ion channels, mi-
tochondria, structural nuclear proteins, phosphatases, pro-
tein synthesis, signaling pathways, DNA chromatin, RNA
transcription, and apoptosis. Kocabas et al. found over
12,000 genes expressed in surplus human MII oocytes
retrieved during IVF from three women [327].
Jones et al. studied human in vivo matured GV, MI, and
MII oocytes and in vitro matured MII oocytes collected from
patients undergoing ovarian stimulation and IVF [328].
Oocyte RNA was extracted and loaded on genome microar-
rays. They found an increase in gene expression in immature
oocytes (GV, 10,962; MI, 12,329) and in vitro mature MII
oocytes (9479) compared with in vivo matured MII oocytes
(7546). In addition, 2000 transcripts were expressed 2-fold
higher in IVM MII oocytes compared with in vivo matured
MII oocytes. These genes are involved in oocyte cellular pro-
cesses including DNA transcription, cell cycle control, cellu-
lar protein metabolism, and signal transduction. The authors
suggest that increased gene expression in immature GV and
IVM oocytes is due to a dysregulation of oocyte gene tran-
scription which may reduce oocyte competence.
Zeng et al. studied the molecular basis of oocyte compe-
tence by comparing gene expression profiles of low compe-
tent, moderate competent, and high competent oocytes. They
compared the gene expression profiles of oocytes from non-
stimulated rhesus female monkeys (0.5–2-mm follicles; low
competence), in vitro matured oocytes from females stimulat-
ed with FSH (moderate competence), and in vivo matured
oocytes from female monkeys stimulated with FSH and
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HCG (3–7-mm follicles; high competence) and compared
subsequent embryo development in these groups [329].
mRNA expression levels of 23 genes expressed in oocytes
and embryos were analyzed with RT-PCR. The major finding
was an increase in oocyte mRNAs in non-stimulated oocytes.
The authors suggest a failure in normal transcriptional silenc-
ing in the oocytes from small < 2.0-mm follicles [330]. The
embryos that developed from these low competent oocytes
showed abnormally reduced gene expression. The authors
conclude that altered transcription in non-stimulated oocytes
from small follicles disrupts oocyte gene regulation, epigenet-
ic modification, and metabolism. These oocyte abnormalities
result in embryo developmental failure.
Grondahl et al. studied mRNA from normal donated MII
oocytes from younger (< 36 years) and older [113–115] wom-
en using whole-genome sequence microarray [88]. A total of
7470 genes/single MII oocyte were identified. They identified
several major functional gene categories including cell cycle,
meiosis and mitosis, spindle function, anaphase-promoting
complex (APC), electron transport chain-mitochondria, and
oxidative stress. A total of 342 genes were differentially
expressed and greater than 2-fold expression was found in
103 genes. These genes included the following: cell cycle
(SMAD2, MAPK4, CDKNIC), meiosis (separase, EMEI),
spindle function (MAD2LI, DOCR1), anaphase-promoting
complex (ubiquilin I, ANAPC4, UBE4B, USP2, USP34,
USP42, USP9X), mitochondrial (mitochondrial fission regu-
lator 1—MtfrI), and DNA repair (nuclear autoantigenic sperm
protein—NASP). These genes may contribute to the age-
associated reduction in oocyte competence.
Grondahl et al. compared molecular pathways involved
in oogenesis in oocyte from human primordial follicles and
MII oocytes [82]. A total of 10,419 total genes and 2228
differentially expressed genes were identified in MII oo-
cytes. The primary molecular pathways represented in MII
oocytes showing 10-fold higher expression included cell
cycle, oocyte maturation, and spindle organization, e.g.,
securin, cyclin B1, separase, CDC20, aurora kinase
(AURKC), BMP15, GDF9, EGF, and EGFR. The authors
state that accumulation of these specific transcripts in MII
oocytes during oogenesis suggests that these genes may be
important for MII oocytes to function. These genes may be
required for the development of oocyte competence.
Riris et al. studied single human MII and GV oocyte
mRNA levels of genes known to be functionally impor-
tant contributors to oocyte quality in mice [80]. MII oo-
cytes that failed to fertilize were studied. Ten genes were
identified: CDK1, WEE2, AURKA, AURKC, MAP2k1,
BUB1, BUB1B, CHEK1, MOS, FYN. mRNA levels were
overall higher in GV oocytes than the MII oocytes.
Individual MII oocyte mRNA abundance levels varied
between patients. And gene expression levels widely var-
ied among individual cell cycle genes in single oocytes.
WEE2 was the highest expressed gene of this group.
BUB1 expression was the lowest, approximately 100-
fold lower than WEE2. Age-related changes were also
observed. AURKA, BUB1B, and CHEK1 were lower in
oocytes from an older patient than oocytes from a younger
patient. The expression and abundance of these transcripts
may reflect the level of oocyte competence.
Yanez et al. studied the mechanical properties, gene expres-
sion profiles, and blastocyst rate of 22 zygotes [81].
Mechanical properties at the zygote stage predicted blastocyst
formation with 90% precision. Embryos that became blasto-
cyst were defined as viable embryos. Single-cell RNA se-
quencing was performed at the zygote stage on viable and
non-viable embryos. They found expression of 12,342 genes,
of which 1879 were differentially expressed between both
groups. Gene ontology clustering on the differentially
expressed genes identified 19 functional clusters involved in
oocyte cytoplasmic and nuclear maturation. At the zygote
stage, all mRNAs, proteins, and cytoplasmic contents origi-
nate from the oocyte. The first two embryo divisions are con-
trolled by maternal genes [331]. Gene deficiencies in cell cy-
cle, spindle assembly checkpoint, anaphase-promoting com-
plex, and DNA repair genes were identified in non-viable
zygotes. Non-viable embryos had reduced mRNA expression
levels of CDK1, CDC25B, cyclins, BUB1, BUB1B, BUB3,
MAD2L1, securin, ANAPCI, ANAPC4, ANAPC11, cohe-
sion complex genes including SMC2, SMC3 and SMC4,
BRCA1, TERF1, ERCC1, XRCC6, XAB2, RPA1, and
MRE11A. The authors suggest that reduced cell cycle tran-
script levels may explain abnormal cell division in cleavage
embryos and blastocyst, and embryo aneuploidy.
Reyes et al. studied molecular responses in 10 oocytes (5
GV, 5 MII) from young women and 10 oocytes (5 GV, 5 MII)
from older women using RNA-Seq sequencing (HiSeq 2500;
Illumina) [79]. Patients were stimulated with FSH and trig-
gered with HCG. GVoocytes were collected and used in this
study. Some GV oocytes were placed in IVM media supple-
mented with FSH, EGF, and BMP. MII oocyte and GVoocyte
total RNA was extracted, cDNAwas synthesized and ampli-
fied and sequenced by single-cell RNA-Seq. Expressed genes
were analyzed using weighted gene correlation network anal-
ysis (WGCNA). This identifies clusters of correlated genes.
They found 12,770 genes expressed per oocyte, transcript
abundance was greater in GV than MII oocytes, 249 (2%)
were specific to MII oocytes, and 255 genes were differential-
ly expressed between young and old MII oocytes. The major
age-specific differentially expressed gene functional catego-
ries identified were cell cycle (CDK1), cytoskeleton, and mi-
tochondrial (COQ3).
These human oocyte studies suggest that oocyte cell cycle
genes are key regulators of oocyte competence. Cell cycle
genes may be expressed 10-fold higher in MII oocytes com-
pared with immature oocytes. These include securin, cyclin
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B1, separase, CDC20, aurora kinase (AURKC), BMP15,
GDF9, EGF, and EGFR. The accumulation of these specific
transcripts inMII oocytes during oogenesis suggests that these
cell cycle genes may be required for the development of oo-
cyte competence. Cell cycle gene expression levels are vari-
able between MII oocytes. Not all MII oocytes are competent.
A unique cell cycle gene expression profile may indicate MII
oocyte competence. Cell cycle gene expression levels are re-
duced in abnormal blastocyst. These human oocyte studies
suggest that cell cycle genes (Table 1) are required for the
acquisition of oocyte competence, and that MII oocytes with
abnormal cell cycle gene expression profiles develop abnor-
mal embryos. Understanding the molecular determinants of
oocyte quality is clinically important. The dramatic reduction
of oocyte quality associated with advancing maternal age is a
major cause of infertility [332]. Currently, there is no effective
treatment to improve reduced oocyte quality.
LH Signaling: Experimental Animal IVM
Studies
In vitro maturation (IVM) oocyte culture systems have im-
proved animal and human oocyte and embryo quality [6,
101]. The rationale of this approach is to synchronize oocyte
nuclear and cytoplasmic maturation prior to completion of the
first meiotic division. Premature resumption of meiosis is
prevented to allow completion of normal nuclear and cyto-
plasmic maturation when oocytes are removed from follicles
at oocyte retrieval. This allows oocyte cell cycle proteins to
accumulate in the nucleus resulting in nuclear maturation.
This also allows normal oocyte growth and duplication of
cytoplasmic contents, i.e., ribosomes, Golgi, and mitochon-
dria, and nuclear contents in preparation for the completion
of the first and second meiotic cellular divisions of the oocyte.
This is accomplished, experimentally, by maintaining high
cAMP levels in the cumulus-oocyte complex (COC) with
phosphodiesterase inhibitors (PDE-I). Phosphodiesterases
(PDE) breakdown cAMP which activates the oocyte CDK1/
cyclin B resulting in resumption of meiosis and completion of
the first meiotic division. Thus, immature incompetent oo-
cytes can grow and develop into competent oocytes by
allowing synchronization of nuclear and cytoplasmic growth.
IVM studies demonstrate that cAMP-modulated IVM oocyte
maturation rates, fertilization rates, and embryo cleavage rates
can be improved. The cattle industry routinely utilizes IVM to
produce healthy embryos. A total of 400,000 healthy cattle
embryos were produced in 2013. Four IVM systems have
been developed: standard IVM, biphasic (moderate cAMP),
moderate induced (moderate cAMP), and high induced (high
cAMP) [6, 101, 333].
Standard IVM protocols culture immature COCs in stan-
dard IVM media without cAMP modulators. IVM media are
supplemented with FSH, LH, or HCG. Immature oocytes rap-
idly undergo spontaneous oocyte meiotic maturation. [165,
334]. Biphasic IVM systems utilize a phosphodiesterase in-
hibitor (PDE-I) for 24 h. This maintains moderate follicle
cAMP levels which prevents oocyte nuclear maturation.
This 24-h phase is followed by a PDE-I free 2nd phase which
allows oocyte maturation to occur. The inhibition of oocyte
nuclear maturation by cAMP was first demonstrated in the
1970s in mice and frogs [167, 335]. This approach improves
mouse [336], bovine [337], and porcine [338] oocyte compe-
tence and embryo quality relative to standard IVM.
Induced IVM (high cAMP) protocols induce high cAMP
levels, with cAMP stimulators, in the COC similar to the
cAMP spike seen in vivo after the LH surge. Aktas et al.
induced high cAMP levels in bovine oocytes with invasive
adenylate cyclase. Ninety percent of the treated oocytes were
maintained in meiotic arrest [339]. Funahashi et al. exposed
porcine oocytes to the cAMP analogue dbc AMP [340]. Even
though the oocyte maturation rate was not improved, oocyte
quality was improved. Blastocyst rates were higher in the
treated group compared with the untreated group (21.5% vs.
9%). Li et al. used forskolin (activates adenylyl cyclase) and
IBMX (PDE-I) to increase follicle cAMP levels. This in-
creased glutathione oocyte levels, reduced hydrogen peroxide
levels, and reduced bovine oocyte oxidative stress. This im-
proved oocyte and embryo quality [341].
Other novel IVM systems have also improved oocyte and
embryo quality. EGF and AREG improve animal oocyte de-
velopmental competence [342]. Ritter et al. studied small (<
4 mm)- and medium-sized (> 4 mm) follicles, which represent
low and moderate oocyte competence, respectively [343].
Denuded oocytes were matured in vitro in standard IVM me-
dia or IVM media supplemented with EGF. Cumulus cell
EGFR gene expression and protein was measured with quan-
titative RT-PCR and western blot. Medium-sized follicles
showed full cumulus cell expansion in response to EGF, while
small follicles failed to expand. CC expansion gene (HAS2,
PTGS2, TNFA1P6) mRNA expression was significantly low-
er in small follicles compared with medium follicles treated
with EGF. EGFR mRNA expression levels were similar in
small- and medium-sized follicles. EGFR protein and EGFR
phosphorylation was increased in moderate- compared with
small-sized follicles. EGF increased EGFR protein and EGFR
phosphorylation in moderate-sized follicles, while EGFR pro-
tein and phosphorylation levels were undetectable in small-
sized follicles. ERK1/2 phosphorylation was higher in
moderate-sized follicles compared with small follicles. To de-
termine whether native OSFs can cause CC expansion in
small follicles, small follicles were co-cultured with denuded
oocytes from medium-sized follicles and treated with EGF.
Small follicles demonstrated full CC expansion. Native
OSFs are probably acting via SMAD 2/3 since a SMAD an-
tagonist prevented CC expansion. GDF9 and BMP15 did not
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induce CC expansion in small-sized follicles. Inseminated oo-
cytes from moderate-sized follicles developed more blasto-
cysts compared with oocytes from small follicles (45% vs.
15%). Small follicles treated with OSFs and EGF developed
more blastocysts compared with those treated with EGF only
(34% vs. 15%). The authors concluded that EGF and OSFs
interact to improve oocyte competence.
OSFs improve oocyte and embryo developmental compe-
tence. Hussein et al. treated bovine COCs with GDF9 or
BMP15 during IVM maturation [344]. The blastocyst rate
was improved compared with controls (55% vs. 40%).
GDF9 improved mouse fetal survival (40% vs. 20%) [345].
BMP15 improved oocyte and embryo quality by stimulating
CC and oocyte gap junction activity [346].
CNP improves animal oocyte quality. Santiquet et al.
preincubated murine COC with CNP, FSH, and BMP15
for 2 or 24 h [347]. Resumption of meiosis was
prevented. Blastocyst rate (71.9% vs. 53.3%) and implan-
tation rate (37.2% vs. 17.2%) were improved compared
with controls after 96 h of culture.
These studies show that oocytes from larger follicles are
more developmentally competent than oocytes from small
follicles. The developmental competence of cultured oocytes
can be improved with IVM protocols supplemented with
cAMP modulators, EGF, AREG, OSFs, and CNP. The acqui-
sition of oocyte competence is dependent on the accumulation
of adequate cumulus cell EGFR, ERK1/2, and SMAD2/3
transcript levels and gap junction activity.
LH Signaling: Experimental Human IVM
Studies
Experimental human IVM studies performed during the last
10 years demonstrate that human oocyte and embryo quality
can be improved (Table 2). Nogueira et al. performed the first
IVM prematuration culture (PMC) human oocyte study. They
studied human GVoocytes retrieved from 12-mm follicles or
less after standard controlled ovarian hyperstimulation (COH)
with FSH and triggered with HCG [93]. COCswere incubated
with a PDE3-I for 24- or 48-h prematuration culture (PMC)
period then washed and cultured in IVM media with FSH and
EGF for 48 h. This was followed by insemination with ICSI;
the embryos were grown for 3 days. In the control IVM group,
COCs were grown in IVMmedia with FSH and EGF for 48 h.
PDE3-I delayed meiotic progression, as 98% of the PDE3-I-
treated GVoocytes remained arrested. PDE3-I-treated GVoo-
cytes achieved higher maturation rates compared with control
oocytes (67 vs. 46%; p = 0.01). The PMC treatment period did
not improve fertilization or cleavage rates. In addition, higher
oocyte maturation rates were found in COCs with moderate
cell expansion compared with compacted COCs.
Shu et al. collected COCs from unstimulated and non-
HCG-triggered 4–10-mm antral follicles by laparoscopy from
292 women mean age 34 [94]. A total of 730 COCs were
cultured in IVM control media, or cilostamide (PDE3-I) alone,
or forskolin (adenylate cyclase activator) alone, and combined
cilostamide and forskolin in a 48-h PMC period followed by
IVM for 24 h. Metaphase II oocytes were inseminated with
ICSI and embryos were grown for 5 days. PDE3-I delayed
meiotic progression. Oocyte maturation and embryo cleavage
rates were similar in all groups (Table 2). The fertilization rate
was increased in the combined groups compared with controls
(52 vs. 76%). Gap junction communication (GJC) was
prolonged 2-fold in the cilostamide + forskolin group com-
pared with control. The authors concluded that the com-
bined treatment, cilostamide and forskolin, increased fol-
licle cAMP, delayed resumption of meiosis, and increased
and maintaining GJC. This resulted in improved oocyte
cytoplasmic maturation, and embryo quality as reflected
in the increase in blastocyst rate. Further IVM studies are
required to determine the optimal agents and dose and
time intervals of PDE-I and AC activators.
Vanhoutte et al. stimulated patients with FSH 150 IU/day
or Menopur (equal amounts of FSH- and HCG-driven LH
activity) and triggered with HCG 5000 IU when two follicles
reached a diameter of 20 mm [95]. GVand MII oocytes were
retrieved from < 10-mm-diameter follicles for the study.
Retrieved MII oocytes were the in vivo controls. IVM media,
Tissue Culture Medium 199, was supplemented with EGF.
PMC media were composed of basal medium (Tissue
Culture Medium 199) supplemented with 0.8% human serum
albumin plus PDE3-I (cilostamide). Cumulus-enclosed oo-
cytes (CEOs) were embedded in an extracellular matrix
(ECM) solution composed of collagen with PMC media for
24 h. The ECM solution allows the CEOs to maintain their
three-dimensional (3D) tight structure. This preserves somatic
cell-oocyte bidirectional communication which promotes oo-
cyte quality. After the 24-h PMC period, COCs were cultured
in IVMmedia for 24, 30, and 48 h. CEO controls were grown
in IVM media only, for 48 h. MII oocytes were fertilized by
ICSI. Fertilization was assessed at 16–18 h post-ICSI.
Embryos were graded on days 2 and 3. PDE3-I delayed mei-
otic progression. Ninety percent of the oocytes grown in 3D
PMC media were arrested at the GV stage. The MII rate
(60.6% vs. 81.6%; p < 0.05), fertilization rate (27.3% vs.
59.6%), and embryo cleavage rate (27.3% vs. 55.6%) were
all higher in the 3D PMC group compared with the IVM
conventional group (Table 2). Electron microscopy studies
found that the 3D PMCmethodmaintained the CEO 3D struc-
ture, cumulus-oocyte contacts were maintained, and
transzonal projections were identified. Lucifer yellow dye
coupling assay identified more functional gap junctions in
the 3D PMC group compared with controls. They concluded
that the 3D PMC period improved oocyte maturation and
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embryo cleavage rates reflecting an improvement in oocyte
quality, and oocyte meiotic and cytoplasmic maturation.
This improved oocyte quality may be related to preservation
of cumulus-oocyte gap junctions.
Novel IVM culture systems supplemented with growth
factors and other signaling molecules improve oocyte quality.
Goud et al. studied the effect of EGF on oocyte quality. They
obtained 289 spare germinal vesicle (GV) oocytes from 92
infertile patients stimulated with human menopausal gonado-
tropin (HMG), which were retrieved 36 h post-HCG
10,000 IU, and then inseminated with ICSI [97]. The mean
age of the patients was 31.8 years. GVoocytes were cultured
in IVM media supplemented with EGF for 12, 24, and 30 h.
GVoocytes were divided into two groups: group I, cumulus-
denuded oocytes with and without EGF and group II, intact
oocytes with and without EGF. At 30 h, the MII rate in the
denuded was higher in the oocytes supplemented with EGF
(64.3% vs. 33.9%) (Table 2). The fertilization rate in the de-
nuded group was similar to that in the EGF- and non-EGF-
supplemented oocytes. In the intact group, the fertilization
rate was higher in the EGF-supplemented oocytes (71.7%
vs. 45.6%). The day 3 cleavage rate was overall higher in
the oocyte-intact EGF group. They concluded that
retaining cumulus cells and adding EGF improve the
MII, fertilization, and cleavage rates. This suggests im-
proved oocyte meiotic and cytoplasmic maturation, and
overall improved oocyte quality.
Ben-Ami et al. reported improved MII and embryo cleav-
age rates with IVM media supplemented with EGF and
AREG [98]. Thirty patients were treated with standard COH
stimulation, retrieval, and ICSI. A total of 105 GV oocytes
were cultured with IVM media supplemented with both
AREG and EREG for 24 h. The MII rate was increased in
the supplemented group (75.5 vs. 36.5%, p < 0.001). The fer-
tilization and cleavage rates were not improved with supple-
mentation; however, the higher MII rate allowed more embry-
os to be produced. This was the first study to show a positive
effect of EGF and AREG on human oocyte maturation rate.
Sanchez et al. reported a new IVM strategy for immature
oocytes retrieved from small follicles (2–6 mm) [99]. Thirty
patients with PCOS, average age 28.9, were stimulated with
Menopur for 3 days. HCG trigger was not given. All follicles
were < 10 mm prior to retrieval. Control COCs were cultured
in IVM media supplemented with HMG and HCG, and cul-
tured for 30 h. In the PMC/CNP group, COCs were collected
in media supplemented with PDE3-I (IBMX), then washed
and cultured in IVM media supplemented with FSH and
CNP for 24 h, and then washed and cultured in IVM media
supplemented with AREG and FSH for 30 h. MII oocytes
were inseminated using ICSI. All experimental blastocysts
were biopsied and analyzed for aneuploidy by next-
generation sequencing (NGS). The oocyte maturation rate
(48% vs. 70%), the day 3 good-quality embryo rate (23%
vs. 43%), and the blastocyst rate (8% vs. 18%) were all in-
creased in the PMC group compared with the control IVM
group (Table 2). Transzonal projections (TZPs) were main-
tained in the PMC group which may explain improved oocyte
competence in this group. The blastocyst aneuploidy rate (3
aneuploid/10) was not increased compared with standard
ART. IVM/PMC with CNP improved oocyte maturation, fer-
tilization, and blastocyst rates. This suggests that oocyte mei-
otic and cytoplasmic maturation and oocyte quality are im-
proved. Whether IVM/PMC systems can reduce embryo an-
euploidy rates is not known.
Madkour et al. reported a new rescue IVM approach [100].
All patients were stimulated with standard FSH doses, trig-
gered with HCG, and oocyte retrieval was performed 36 h
post-HCG. MII oocytes were inseminated with ICSI and cul-
tured 5 or 6 days. They randomized 150 GVoocytes from 47
patients with PCOS. Immature GVoocytes were randomized
to four groups. The simple-IVM (S-IVM) protocol contained
standard IVM media. In the autologous follicular fluid (AFF-
IVM) protocol, AFF was added to standard IVM media. AFF
was collected from the study patients during the oocyte re-
trieval. In the heterologous follicular fluid (HFF-IVM) proto-
col, HFF was added to standard IVM media. HFF was taken
from 7 women without PCOS with subsequent 100% MII
maturation. HFF was added to standard IVM media. In the
heterologous follicular fluid/CGC (HFF/CGC-IVM) protocol,
HFF and cumulus-granulosa cell (CGC) supernatant were
added. CGC supernatant was obtained from 7 women without
PCOS. FF was collected at egg retrieval, centrifuged, CGCs
were collected and cultured for 3 days, and then supernatant
was collected and added to IVM media. Immature oocytes
were cultured for 24 h. All IVM-matured MII oocytes were
inseminated with ICSI and cultured to day 5 or 6. The MII,
cleavage, and blastocyst rates were higher in the HFF/CGC-
IVM group compared with standard IVM (Table 2). The CGC
supernatant contains growth factors and cytokines which may
be responsible for the improvement in maturation rate and
embryo quality. The MII maturation rate in the HFF/CGC
group of 79% and 65% day 5 blastocyst rate are similar to
standard IVF MII and blastocyst rates.
Spits et al. treated 16 young (mean age was 28.7) PCOS
women with Menopur 150 IU/day starting on day 3 of the
cycle for 3 days; ultrasound was performed on day 6, and
retrieval for immature oocytes was performed on day 7 on
all patients 42 h after the last dose of Menopur [96]. HCG
trigger was not given. COC oocytes were treated with
PDE3-I (IBMX) for 1 h in standard IVM media. COCs were
then washed and placed in IVM culture media supplemented
with FSH for 40 h, then the cumulus layer was removed,
oocyte maturation was assessed, and ICSI was performed.
The oocyte maturation rate was 50.2% (120/239), the fertili-
zation rate was 68.3% (82/120), and the day 3 cleavage good-
quality embryo rate was 30.5% (25/82). Chromosome
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analysis was performed on single blastomeres. Eighteen em-
bryos were dissociated, individual blastomeres were washed,
136 cells were successfully amplified and analyzed with
aCGH, and 123 cells gave results. Sixty-one percent (11/18)
of the IVM embryos were mosaics. This is similar to the day 3
embryo mosaic rate in standard IVF.
These human IVM studies demonstrate that human oocyte
quality can be improved. IVM/PMC culture systems supple-
mented with PDE-I, EGF, AREG, or CNP improve oocyte
maturation, cleavage rate, and blastocyst rate compared with
standard IVM systems (Table 2). IVM/PMC with PDE-I de-
lays resumption of meiotic maturation by increasing cAMP in
the COC. This allows the cytoplasmic and nuclear contents of
the oocyte to grow and develop, thus allowing time for oocyte
meiotic and cytoplasmic maturation. Improved oocyte meiotic
maturation resulted in MII rates approaching 80%. As a result
of improved oocyte cytoplasmic maturation, the IVM fertili-
zation rate approached 80%, and cleavage rate approached
50–70%. These IVM rates suggest that IVM may become a
routine alternative ART for some patients in the near future.
Oocyte and follicle gap junction activity and transzonal pro-
jections allowing bidirectional communication between
oocyte-granulosa cells may be important mechanisms under-
lying oocyte quality. These studies also suggest that IVM/
PMC system embryo aneuploidy rates and mosaicism are
not increased compared with standard IVF.
Clinical Human IVM
The first human oocyte IVM studies were performed
over 50 years ago [334, 348]. The first successful human
IVM births were reported over 25 years ago [349, 350].
During the first 20 years of IVM, the pregnancy rates
from IVM cycles were reduced by half compared with
standard IVF [351–355]. The reduced IVM pregnancy
rate was attributed to asynchrony between nuclear and
cytoplasmic maturation [356].
Recent IVM studies demonstrate improved outcomes
[357–360]. Walls et al. recently performed the first study that
compared IVM and standard IVF blastocyst development
[361]. They studied 56 PCOS patients (80 cycles) who were
treated with IVM and 65 PCOS patients (98 cycles) treated
with standard IVF. The IVM patients were treated with Gonal-
F (recombinant FSH) 150 IU/day started on cycle day 2 after
transvaginal ultrasound and was continued for 3–6 days.
Transvaginal ultrasound was repeated on day 6 of the cycle,
and oocyte retrieval was performed within 72 h after a 10-mm
follicle was observed. COCswere cultured for 24 h in G-2Plus
media which is a bicarbonate-buffered media with hyaluronan
and maternal serum. This was supplemented with FSH and
hCG. MII oocytes were inseminated with ICSI. The total
number of oocytes retrieved per patient was similar in the
IVM and IVF groups (13.2 vs. 16.6%). The maturation rate
(73 vs. 80%) and fertilization rate (68 vs. 77%) were superior
in the IVF group, and the good-quality blastocyst rate was the
same in both groups (38 vs. 40%). The live birth rate per
transfer was superior in the IVF fresh transfer group compared
with the IVM group (18.8 vs. 31.0%), and similar in the frozen
IVM and IVF groups (33.9 vs. 29.9%). The cumulative live
birth rate per egg retrieved was higher in the IVF group (41.3
vs. 55.1%). The miscarriage rate was higher in the fresh trans-
fer IVM group compared with the fresh IVF group (36.8 vs.
19.0%), and lower in the frozen transfer IVM group compared
with the frozen IVF group (4.5 vs. 18.6%). The birth weights
and preterm labor rate were similar in both groups. The au-
thors concluded that the efficiency gap between IVM and IVF
is closing, and that IVM should be recommended for PCOS
patients who have experienced OHSS with standard IVF.
Birth outcomes are similar in IVM and IVF children.
Preterm birth rates and newborn birth weights are similar in
IVM and IVF births [362, 363]. Congenital birth defects are
not increased in IVM children [364, 365]. Childhood devel-
opment is similar in IVM and IVF. Roesner et al. studied 21
children conceived by IVM [366]. At birth, weight, length,
and head circumference were similar in IVM children com-
pared with IVF controls. At age 2, weight, length, and head
circumference and cognitive development were similar in
IVM compared with IVF controls.
Summary
Here, we reviewed human LH signaling oocyte meiotic mat-
uration studies.We found 89 human studies in the literature on
this topic. These studies identified and characterized 24 LH
signaling proteins involved in oocyte meiotic maturation
(Table 1). Coticchio et al. recently reviewed human oocyte
maturation and similarly found < 50 human studies in the
literature on this topic [5]. These human studies suggest that
the primary targets of the LH signal in the follicle are the CNP/
NPR2 system, the EGF/EGF receptor network, and gap junc-
tions. The primary target of the LH signal in the oocyte is the
MPF (CDK1/Cyclin B1). The activatedMPF initiates resump-
tion of meiosis by phosphorylating downstream proteins in-
cluding SAC proteins, APC proteins, separase, securin, and
cohesin. How these downstream proteins induce resumption
of meiosis and completion of the first meiotic division includ-
ing germinal vesical breakdown, chromosome condensation,
and extrusion of the first polar body in humans is not known.
Additionally, these LH signaling molecules may predict oo-
cyte quality, a critical issue in assisted reproductive technolo-
gy (ART); however, a reliable marker of oocyte quality still
has not been identified.
These LH signaling pathway molecules also regulate oo-
cyte competence. Human oocyte gene expression studies sug-
gest that oocyte cell cycle proteins targeted by the LH signal
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are key regulators of oocyte developmental competence.
Differences in cell cycle gene expression have been identified
between human immature oocytes from primordial follicles
and MII oocytes. Grondahl et al. found differences in securin,
cyclin B1, separase, CDC20, aurora kinase (AURKC),
BMP15, GDF9, EGF, and EGFR [82]. Riris et al. studied
single human MII and GV oocyte cell cycle mRNA levels
and found differences in CDK1, WEE2, AURKA, AURKC,
MAP2k1, BUB1, BUB1B, CHEK1, MOS, and FYN [80].
Yanez et al. found differences in cell cycle gene expression
profiles of viable and non-viable zygotes including CDK1,
CDC25B, cyclins, BUB1, BUB1B, BUB3, MAD2L1,
securin, ANAPCI, ANAPC4, ANAPC11, cohesion complex
genes including SMC2, SMC3, and SMC4, BRCA1, TERF1,
ERCC1, XRCC6, XAB2, RPA1, and MRE11A [81].
Reyes et al. studied cell cycle expression profiles in 10
oocytes (5 GV, 5 MII) from young women and 10 oocytes
(5 GV, 5 MII) from older women [79]. They found differ-
ences in CDK1. These studies suggest that the expression
and abundance of these oocyte cell cycle transcripts may
determine whether an oocyte acquires competence, and
whether it is able to form a viable embryo.
Human oocyte quality can be improved with IVM/PMCma-
nipulation of the LH signaling pathway (Table 2). Human oo-
cyte IVM cultures supplemented with PDE-I [95], AREG [98],
CNP [99], and heterologous follicular fluid/CGC [100] improve
oocyte maturation and embryo quality. Experimental IVM oo-
cyte maturation rates (range, 70–81.6%) are approaching stan-
dard IVF maturation rates. Clinical IVM neonatal outcomes are
similar to standard IVF outcomes. The IVM aneuploidy rate is
not increased in day 3 embryos [96] and blastocysts [99]. These
experimental IVM protocols may soon be introduced into clin-
ical IVM practice further improving clinical IVM.
Conclusion
We found 89 papers in the literature that studied human LH
signaling oocyte meiotic maturation. These studies identified
24 proteins involved in this process (Table 1). The proteins
expressed in the human ovarian follicle compartment are sig-
naling proteins, while the proteins expressed in human oo-
cytes are primarily cell cycle proteins. The primary targets of
the LH signal in the follicle are the CNP/NPR2 system, EGF
network, and gap junctions (Fig. 2). The primary target of the
LH signal in the oocyte is the CDK1/Cyclin B complex. These
follicle/oocyte proteins are vitally important. They regulate
human oocyte meiotic maturation, oocyte quality, and embryo
quality. Remarkably, human oocyte and embryo quality is
improved using IVM/PMC cumulus-oocyte culture systems
that manipulate the LH signaling pathway (Table 2). The stud-
ies reviewed were mostly published during the last 10 years.
Human oocyte maturation studies are very limited in number.
Human oocyte research is only beginning. Hopefully, human
oocyte and embryo research will continue to increase in the
future so that further insight into the cellular mechanisms that
regulate oocyte and embryo quality can be acquired.
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